Seattle Biopharma Omeros Raises $22M Through Stock Sale

Seattle-based Omeros Corp. is raised $22M through a registered direct offering announced July 25. The company sold nearly 5.4 million shares at $4.10 each, a 14% premium over its previous closing price, to Toronto-based Polar Asset Management Partners. Founded in 1994, Omeros develops treatments for cancer, addiction, and compulsive disorders, including its drug candidate narsoplimab, designed to reduce vascular inflammation and damage.